NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
OPTIVAR (azelastine hydrochloride) by Gen Pharmaceuticals is hydrochloride, a phthalazinone derivative, exhibits histamine h 1 -receptor antagonist activity in isolated tissues, animal models, and humans. First approved in 2000.
Drug data last refreshed 18h ago
Mechanism of Action
hydrochloride, a phthalazinone derivative, exhibits histamine H 1 -receptor antagonist activity in isolated tissues, animal models, and humans. Azelastine hydrochloride Nasal Spray is administered as a racemic mixture with no difference in pharmacologic activity noted between the enantiomers in in…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis
Started Feb 2020
110 enrolled
Allergic Rhinitis
Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™
Started Aug 2014
1,535 enrolled
Seasonal Allergic Rhinitis
A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
Started Feb 2008
70 enrolled
Allergic RhinitisRhinitis, Allergic, Seasonal
Worked on OPTIVAR at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.